HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma
OPEN BMC cancer | 15 Feb 2018
A Arjona-Sánchez, P Barrios, E Boldo-Roda, B Camps, J Carrasco-Campos, V Concepción Martín, A García-Fadrique, A Gutiérrez-Calvo, R Morales, G Ortega-Pérez, E Pérez-Viejo, A Prada-Villaverde, J Torres-Melero, E Vicente, P Villarejo-Campos, JM Sánchez-Hidalgo, A Casado-Adam, R García-Martin, M Medina, T Caro, C Villar, E Aranda, MT Cano-Osuna, C Díaz-López, E Torres-Tordera, FJ Briceño-Delgado and S Rufián-Peña
Local relapse and peritoneal carcinomatosis (PC) for pT4 colon cancer is estimated in 15,6% and 36,7% for 12 months and 36 months from surgical resection respectively, achieving a 5 years overall survival of 6%. There are promising results using prophylactic HIPEC in this group of patients, and it is estimated that up to 26% of all T4 colon cancer could benefit from this treatment with a minimal morbidity. Adjuvant HIPEC is effective to avoid the possibility of peritoneal seeding after surgical resection. Taking into account these results and the cumulative experience in HIPEC use, we will lead a randomized controlled trial to determine the effectiveness and safety of adjuvant treatment with HIPEC vs. standard treatment in patients with colon cancer at high risk of peritoneal recurrence (pT4).
* Data courtesy of Altmetric.com